{"id":68127,"date":"2026-11-04T19:19:19","date_gmt":"2026-11-04T19:19:19","guid":{"rendered":"https:\/\/cp.snarskis.lt\/index.php\/2026\/11\/04\/kopenhagos-biograil-pritrauke-20-mln-euru-kapsulei-kuri-galetu-pakeisti-injekcijas\/"},"modified":"2026-11-04T19:19:19","modified_gmt":"2026-11-04T19:19:19","slug":"kopenhagos-biograil-pritrauke-20-mln-euru-kapsulei-kuri-galetu-pakeisti-injekcijas","status":"publish","type":"post","link":"https:\/\/cp.snarskis.lt\/index.php\/2026\/11\/04\/kopenhagos-biograil-pritrauke-20-mln-euru-kapsulei-kuri-galetu-pakeisti-injekcijas\/","title":{"rendered":"Kopenhagos \u201eBiograil\u201c pritrauk\u0117 20 mln. eur\u0173 kapsulei, kuri gal\u0117t\u0173 pakeisti injekcijas"},"content":{"rendered":"

Kopenhagoje \u012fsik\u016brusi biotechnologij\u0173 bendrov\u0117 \u201eBiograil\u201c u\u017esitikrino 20 mln. eur\u0173 investicij\u0105 \u012f geriam\u0105 vaist\u0173 pristatymo \u012frengin\u012f, kuriuo siekiama dal\u012f injekcij\u0173 pakeisti kapsul\u0117mis.<\/p>\n

Apie finansavimo etap\u0105 prane\u0161\u0117 \u201eEU-Startups\u201c \u2013 j\u012f par\u0117m\u0117 \u201eVerve Ventures\u201c ir \u201eMegatrend Invest\u201c, taip pat prisid\u0117jo \u201eHigh-Tech Gr\u00fcnderfonds\u201c (HTGF) per savo \u201eOpportunity\u201c augimo fond\u0105.<\/p>\n

\u012emon\u0117, \u012fkurta 2019 metais, teigia kurianti nuosav\u0105 BIONDD technologij\u0105, skirt\u0105 vaistams, kuriuos \u012fprastai tenka leisti injekcijomis, pristatyti per burn\u0105 \u2013 kapsul\u0117s forma.<\/p>\n

Tokie sprendimai aktual\u016bs tod\u0117l, kad injekcijos daliai pacient\u0173 kelia papildom\u0173 nepatogum\u0173, o geriamas formatas gal\u0117t\u0173 supaprastinti vartojim\u0105, jei pasiteisins klinikiniuose etapuose.<\/p>\n

Kaip veikia BIONDD kapsul\u0117<\/h2>\n

Pasak \u201eBiograil\u201c, \u012frenginys telpa \u012f standartinio dyd\u017eio \u201edouble-zero\u201c arba \u201esingle-zero\u201c kapsul\u0119, kuri\u0105 tur\u0117t\u0173 b\u016bti lengva nuryti.<\/p>\n

Kapsulei i\u0161tirpus skrandyje, joje esantis \u012frenginys i\u0161silaisvina: apra\u0161oma, kad jis turi spyruoklin\u012f \u201esugriebimo\u201c mechanizm\u0105, leid\u017eiant\u012f saugiai prisitvirtinti prie skrand\u017eio sienel\u0117s.<\/p>\n

Tuomet vaistas i\u0161leid\u017eiamas \u012f audin\u012f taip, kad gal\u0117t\u0173 pasiskirstyti organizme sistemi\u0161kai. Bendrov\u0117 pabr\u0117\u017eia, kad po vaisto pristatymo bio-kompostuojamas \u012frenginys tur\u0117t\u0173 saugiai pasi\u0161alinti per vir\u0161kinam\u0105j\u012f trakt\u0105.<\/p>\n

Kur bus nukreiptos investicijos<\/h2>\n

\u201eBiograil\u201c teigia, kad pritrauktas kapitalas bus naudojamas planuojamiems 1 faz\u0117s klinikiniams tyrimams pasirengti ir juos \u012fgyvendinti.<\/p>\n

Tarp nurodom\u0173 darb\u0173 \u2013 neklinikiniai GLP tyrimai bei gamybos GMP proceso suk\u016brimas prie\u0161 didesn\u012f finansavimo etap\u0105, kur\u012f \u012fmon\u0117 sieja su 2027 metais.<\/p>\n

\u012emon\u0117s vadovas Karstenas Lindhardtas sak\u0117, kad papildomas kapitalas ir partneryst\u0117s pad\u0117s toliau stumti BIONDD technologij\u0105 link 1 faz\u0117s klinikini\u0173 studij\u0173.<\/p>\n

Kas dalyvauja investuotoj\u0173 rate<\/h2>\n

Finansavimo etape dalyvavo ir HTGF, kuris, kaip nurodoma, vadovavo pradiniam \u012fmon\u0117s investuotoj\u0173 sindikatui dar 2019 metais.<\/p>\n

\u201eBiograil\u201c investuotoj\u0173 s\u0105ra\u0161e taip pat minimi \u201eEli Lilly and Co.\u201c, \u201eSanner Ventures\u201c, \u201eEvonik Venture Capital\u201c, \u201eAnobis GmbH\u201c, \u201eRoquette Ventures\u201c ir kiti.<\/p>\n

Bendrov\u0117 pabr\u0117\u017eia, kad jos komandoje \u2013 patyr\u0119 biotechnologij\u0173 verslo k\u016br\u0117jai ir tyrim\u0173 bei pl\u0117tros vadovai, dirb\u0119 su sprendimais, kuri\u0173 pagrindu sukurta injekciniu b\u016bdu formuojama geriamoji tablet\u0117, patvirtinta JAV FDA.<\/p>\n","protected":false},"excerpt":{"rendered":"

Kopenhagos \u201eBiograil\u201c pritrauk\u0117 20 mln. eur\u0173 geriamai kapsulei su BIONDD \u012frenginiu, kuriuo siekiama dal\u012f injekcij\u0173 pakeisti tablet\u0117mis.<\/p>\n","protected":false},"author":0,"featured_media":68128,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[94],"tags":[53144,53145,4093,6712,1040,29262,53146],"miestas":[],"class_list":["post-68127","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finansai","tag-biograil","tag-biondd","tag-biotechnologijos","tag-kopenhaga","tag-startuoliai","tag-vaistu-pristatymas","tag-verve-ventures"],"acf":[],"_links":{"self":[{"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/posts\/68127","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/comments?post=68127"}],"version-history":[{"count":0,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/posts\/68127\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/media\/68128"}],"wp:attachment":[{"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/media?parent=68127"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/categories?post=68127"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/tags?post=68127"},{"taxonomy":"miestas","embeddable":true,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/miestas?post=68127"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}